Healthy Volunteers (HV)Phase 1NCT07525947
A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants
A Phase 1 study testing JADE101 in people with Healthy Volunteers (HV), run by Jade Biosciences, Inc. at 1 site in United States.
Trial summary
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers (HV)
- What is being tested?
- JADE101
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- 1 May 2026to May 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male or female participants 18-55 years of age, inclusive
- First-generation Japanese or Chinese participants born in Japan/China
- A body weight between 40-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg/m2 (all inclusive) at screening
- Willing and able to comply with the study site stay, scheduled visits, and study procedures
- Willing and able to comply with contraceptive and lifestyle requirements from admission through the end of the study
Who cannot join
- Harmful alcohol use
- Smoking/vaping or heavy tobacco use within 2 years prior to screening
- Known history of abuse of illicit drugs
- Nursing, lactating or pregnant, or who have plans to become pregnant during the study
- Known history of clinically significant disease
- Known history of immunodeficiency disorder
- History of clinically significant allergic reactions or hypersensitivity
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Parexel Early Phase Clinical Unit (EPCU)
Glendale, California, 91206
Han, +1-888-228-7425, study.losangeles@parexel.com
About this study
Official title: A Phase 1, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Japanese and Chinese Participants.
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.
- Conditions
- Healthy Volunteers (HV)
- Being tested
- JADE101
- Keywords
- JADE101
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JADE101Drug
JADE101 is supplied as sterile solution to be administered by SC injection
| Study group | Role | What they receive |
|---|---|---|
| JADE101 Groups 1 and 2 | Experimental | Subcutaneous (SC) injection of JADE101 Receives: Drug: JADE101 |
| JADE101 Groups 3 and 4 | Experimental | Subcutaneous (SC) injection of JADE101 Receives: Drug: JADE101 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participants
Incidence of treatment-emergent adverse events
Measured: Day 1 through 48 weeks
Cmax
Maximum observed serum concentration
Measured: Day 1 through 48 weeks
Tmax
Time to reach Cmax
Measured: Day 1 through 48 weeks
AUClast
The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration
Measured: Day 1 through 48 weeks
T1/2
Apparent first-order terminal elimination half-life
Measured: Day 1 through 48 weeks
Secondary outcomes (1)
Immunogenicity of JADE101 in healthy Japanese and Chinese participants
Incidence and titers of serum anti-drug antibodies (ADAs)
Measured: Day 1 through 48 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Apr 2026
- Study start1 May 2026
- Primary completionMay 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Volunteers (HV)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Jade Biosciences, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Li Li, MD, Study director, Jade Biosciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07525947
- Sponsor's protocol ID
- JADE101-05
- Status last verified
- Jun 2026
- First submitted
- 6 Apr 2026
- Last updated
- 4 Jun 2026
- Results posted
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JADE101 Administered Subcutaneously in Healthy Japanese and Chinese Participants.
- ClinicalTrials.gov ID
- NCT07525947
- Acronym / sponsor ID
- JADE101-05
- Conditions
- Healthy Volunteers (HV)
- Keywords
- JADE101
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Jade Biosciences, Inc.Industry (pharma, biotech, devices)
- Study start
- 1 May 2026 (actual)
- Primary completion
- May 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 13 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.
Study design
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| JADE101 Groups 1 and 2 | Experimental | Drug: JADE101Subcutaneous (SC) injection of JADE101 |
| JADE101 Groups 3 and 4 | Experimental | Drug: JADE101Subcutaneous (SC) injection of JADE101 |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Healthy male or female participants 18-55 years of age, inclusive
- First-generation Japanese or Chinese participants born in Japan/China
- A body weight between 40-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg/m2 (all inclusive) at screening
- Willing and able to comply with the study site stay, scheduled visits, and study procedures
- Willing and able to comply with contraceptive and lifestyle requirements from admission through the end of the study
Key exclusion criteria (7 listed)
- Harmful alcohol use
- Smoking/vaping or heavy tobacco use within 2 years prior to screening
- Known history of abuse of illicit drugs
- Nursing, lactating or pregnant, or who have plans to become pregnant during the study
- Known history of clinically significant disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JADE101JADE101 is supplied as sterile solution to be administered by SC injection | Drug | JADE101 Groups 1 and 2, JADE101 Groups 3 and 4 |
Primary outcome
Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participants
Time frame: Day 1 through 48 weeks
Incidence of treatment-emergent adverse events
Cmax
Time frame: Day 1 through 48 weeks
Maximum observed serum concentration
Tmax
Time frame: Day 1 through 48 weeks
Time to reach Cmax
AUClast
Time frame: Day 1 through 48 weeks
The area under the concentration-time curve from time zero to the time of the last observed quantifiable (non-zero) concentration
T1/2
Time frame: Day 1 through 48 weeks
Apparent first-order terminal elimination half-life
1 secondary outcome
Immunogenicity of JADE101 in healthy Japanese and Chinese participants
Time frame: Day 1 through 48 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Healthy Volunteers (HV)
RecruitingObservational study
Imaging Techniques in MRI
Cardiac Risk Factors, Healthy
RecruitingObservational study
Collection of Lung Fluid and Tissue Samples for Research
Leukocyte Disorders, Respiratory Tract Diseases
RecruitingObservational study
Screening for LID Clinical Studies Unit Healthy Volunteer Protocols
Zika, Influenza
RecruitingObservational study
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
Mood Disorders, Anxiety Disorders
RecruitingObservational study
Defining the Brain Phenotype of Children With Williams Syndrome
Williams Syndrome, Duplication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Li Li, MD study director
Jade Biosciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing JADE101 in people with Healthy Volunteers (HV), run by Jade Biosciences, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Han (+1-888-228-7425, study.losangeles@parexel.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and tolerability of single dose of JADE101 in healthy Japanese and Chinese participants (time frame: Day 1 through 48 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2026.